Although small- and medium-sized biotechs are absent from the NIH's new Accelerating Medicines Partnership with industry and not-for-profit organizations, consortium leaders expect that making results publicly available on their search for new targets and biomarkers in four diseases will benefit all players. However, it is unclear whether the $230 million, 5-year fund is adequately financed to meet the partnership's goal of accelerating target discovery.
The public-private partnership (PPP) includes 10 companies,
5 disease-oriented not-for-profit organizations and the Pharmaceutical Research and Manufacturers of America (PhRMA) (see "Participants in the NIH AMP consortium"). The operations and governance of the PPP will be managed by the Foundation for the National Institutes of Health (FNIH), a not-for-profit entity set up in the early 1990s to support the NIH by forming and facilitating PPPs for biomedical research and training.
The NIH and industry partners are contributing equally to the total fund for the Accelerating Medicines Partnership (AMP). In addition, some not-for-profit organizations are giving financial support, and all parties are making in-kind contributions such as scientists, expertise, technology and access to patient samples.
The NIH's share of the AMP budget is coming from the NIH institutes responsible for the therapeutic areas being investigated-Alzheimer's disease (AD), type 2 diabetes, rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) (see Table 1, "Participants in the NIH AMP consortium").
About $130 million will go to AD projects, $58 million to type 2 diabetes